Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arbutus Biopharma

3.30
-0.0200-0.60%
Post-market: 3.300.00000.00%19:41 EDT
Volume:707.42K
Turnover:2.36M
Market Cap:625.32M
PE:-7.74
High:3.41
Open:3.34
Low:3.29
Close:3.32
Loading ...

Arbutus Biopharma Corp : Chardan Capital Markets Raises Target Price to $5 From $4.5

THOMSON REUTERS
·
20 Nov 2024

Arbutus Biopharma price target raised to $5 from $4.50 at Chardan

TIPRANKS
·
20 Nov 2024

Arbutus Biopharma: Promising Developments and Positive Outlook Boost Buy Rating

TIPRANKS
·
19 Nov 2024

Arbutus Biopharma Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow Jones
·
18 Nov 2024

Arbutus Biopharma’s Promising Breakthrough in Chronic Hepatitis B Treatment Justifies Buy Rating

TIPRANKS
·
18 Nov 2024

Arbutus Trial of Combination Therapy for Chronic Hepatitis B Shows 'Promising' Results

MT Newswires Live
·
16 Nov 2024

BRIEF-Arbutus & Barinthus Bio Announce New Data From The IM-PROVE II Trial

Reuters
·
16 Nov 2024

Arbutus Biopharma’s Promising cHBV Treatment Results

TIPRANKS
·
16 Nov 2024

Arbutus Biopharma’s Trial Boosts Hepatitis B Treatment

TIPRANKS
·
16 Nov 2024

Arbutus Biopharma announces new data from IM-PROVE I Phase 2a trial

TIPRANKS
·
16 Nov 2024

Arbutus and Barinthus announce new data from IM-PROVE II trial

TIPRANKS
·
16 Nov 2024

Arbutus and Barinthus Bio Announce New Data From the IM-Prove Ii Trial Showing That the Addition of Nivolumab Increased Rates of Hbsag Loss in People With Chronic Hepatitis B

THOMSON REUTERS
·
16 Nov 2024

Arbutus Biopharma Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow Jones
·
07 Nov 2024

Promising Potential of Arbutus Biopharma’s Imdusiran in Achieving Functional Cure for Hepatitis B: Ed Arce’s Buy Rating

TIPRANKS
·
07 Nov 2024

Arbutus Biopharma Corp (ABUS) Q3 2024 Earnings Call Highlights: Promising Clinical Trials and ...

GuruFocus.com
·
07 Nov 2024

Q3 2024 Arbutus Biopharma Corp Earnings Call

Thomson Reuters StreetEvents
·
07 Nov 2024